Cardiovascular Drugs And Cancer Risk: A Dissenter’s View
This article was originally published in RPM Report
Executive Summary
Here is an excerpt from FDA medical reviewer Thomas Marciniak’s “special review” submitted as part of the record for FDA’s review of Pfizer/Bristol-Myers Squibb’s Eliquis (apixaban). In it, he calls for public discussion of cancer risks associated with anti-clotting drugs like apixaban—and angiotensin receptor blocker antihypertensives. The email exchange released in this review was the basis for media coverage of the “debate” within FDA over the link between ARBs and lung cancer.
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: